2015 Patients Provider Vaccination 
Annals of Family Medicine
NOVEMBER 20, 2024
Context: The human papillomavirus (HPV) vaccine is recommended starting at age 9 to reduce risk of HPV linked squamous cell cancers, yet recent data shows that only 58.6% have been vaccinated by age 17. Secondary acceptance is agreeing to a vaccine subsequent to declining in a previous encounter.
FDA Law Blog
AUGUST 21, 2023
After all, the labeling is intended to do exactly that: it informs patients and prescribers of the risks to ensure the product is used effectively and in a manner that mitigates risks, according to FDA’s understanding of the relevant science. But we digress.
FDA Law Blog
SEPTEMBER 14, 2021
Under all of these programs, patient co-insurance would be calculated based on the MFP so that patients receive the benefit of that price. A manufacturer that failed to provide access to the MFP would be subject to a civil monetary penalty of ten times the excessive price charged. 8126 with a lower MFP.
Expert insights. Personalized for you.
130 
Let's personalize your content